Joe Podojil

Company: COUR Pharmaceuticals

Job title: Director - Immunology

Seminars:

Showcasing the Antigen-Specific CNP Nanoparticle Treatment Regulates CD8+ T Cells in a Model of Type 1 Diabetes 11:00 am

• Developing nanoparticles that bind to monocytes and enhance uptake • Ensuring optimal, targeted delivery of ASIT therapies through nanoparticles • Harnessing COUR’s nanoparticle technology to reprogram the immune system for a breakthrough approach to treating autoimmune diseaseRead more

day: Custom Day Two

Panel: Debating the Need for Autoantigens Vs Tissue Specific Antigens 12:00 pm

• Understanding the interplay between disease-specific and tissue-specific antigens • Addressing the challenges posed by antigen heterogeneity using T1D as a case study • Is having a strong pancreatic antigen to induce Tregs in the pancreas enough to trigger antigen-specific immunity in T1D patients?Read more

day: Seminar Day pt 2